Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) receptor which reduces appetite and slows gastric emptying [6] [7] GIP (glucose-dependent insulinotropic polypeptide) receptor which enhances insulin secretion and may improve fat metabolism [9] [10] Glucagon receptor which may increase energy expenditure and, based on early clinical and preclinical data, could promote hepatic fat metabolism This triple-action mechanism sets retatrutide apart from existing approved therapies such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist)
This is when consistent weight loss usually begins
Biological chemistry , 390 (3), 191-214
[PMID: 7325958] PubMed record related to this compound for laboratory literature review
Your health is worth the investment, and your body has remarkable capabilities when given the right nutritional foundation
Verifiable billing error: A full refund may be issued if altRx made a verifiable billing error, such as an incorrect or duplicate charge